Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0518 versus Kaletra switch study in HIV-infected adults
2007-000783-25Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing MK-0518 switch arm with Kaletra control arm (2 arms). Primary endpoint: Proportion of patients with plasma HIV RNA <50 copies/mL at Week 24. Started Mar 2007; status: terminated.
02
Drugs
lopinavir + ritonavirraltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2007-000783-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000783-25.